Bital Savir-Baruch

Chief, Division of Nuclear Medicine and Molecular Imaging | Professor, Medical Imaging - (Clinical Scholar Track)

Research Area

prostate cancer, pet/ct imaging, medical imaging, imaging, cancer, positron emission tomography, pet imaging, radiopharmaceuticals, clinical trials, biochemical recurrence, clinical trial, radiology, fluciclovine, 18f-fluciclovine, radiation therapy, nuclear medicine

A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated
Active·2024·$0 / $7.5M·
External
Co-Investigator (COI)
immunotherapy, cancer treatment, biopharmaceuticals, clinical trials, monoclonal antibodies
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphom
Active·2024·$0 / $1.2M·
External
Co-Investigator (COI)
lymphoma, efficacy, safety, treatment, clinical trial
Feasibility of Fluciclovine PET/CT to Identify Brain Metastasis
Active·2024·$212.8K·
External
Principal Investigator (PI)
cancer, imaging, brain, metastasis, feasibility

Recent

Computer assisted interpretation of Tc-99m mercaptoacetyltriglycine diuretic scintigraphy enhances resident performance

2023

nuclear medicine, diuretic scintigraphy, computer-assisted interpretation, resident performance, medical imaging technology

Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer

2023

ovarian cancer, radiotracer imaging, pet/ct imaging, 18f-fluciclovine, diagnostic imaging

Impact of F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials

2023

prostate cancer, pet/ct imaging, androgen deprivation therapy, biochemical recurrence, clinical trials

Diagnostic Performance and Safety of F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study SPOTLIGHT)

2023

prostate cancer, positron emission tomography, diagnostic performance, cancer recurrence, safety

Diagnostic Performance and Safety of Positron Emission Tomography with F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study LIGHTHOUSE)

2023

cancer imaging, prostate cancer, positron emission tomography, diagnostic performance, safety assessment

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 Lu-177) DOTATATE Therapy

2022

nuclear medicine, radiology, oncology, therapy, medical physics

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

2022

medical imaging, prostate cancer, diagnostic criteria, pet imaging, clinical guidelines

Effect of hormonal therapy on F-fluciclovine PET/CT in the detection of prostate cancer recurrence, localization of metastatic disease, and correlation with prostate-specific antigen

2022

prostate cancer, hormonal therapy, pet/ct imaging, metastatic disease, prostate-specific antigen

Positivity Rate of F]Fluciclovine PET/CT in Patients with Suspected Prostate Cancer Recurrence at PSA Levels Below 1 ng/mL

2022

cancer, imaging, positivity, recurrence, diagnosis

Prostate Cancer Imaging with 18F-Fluciclovine

2022

prostate cancer, imaging, 18f-fluciclovine, cancer, radiology

Page 1 of 2

Bital Savir-Baruch

Research Area

Grants(3)

A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphom

Feasibility of Fluciclovine PET/CT to Identify Brain Metastasis

Publications(41)

Computer assisted interpretation of Tc-99m mercaptoacetyltriglycine diuretic scintigraphy enhances resident performance

Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer

Impact of F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials

Diagnostic Performance and Safety of F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study SPOTLIGHT)

Diagnostic Performance and Safety of Positron Emission Tomography with F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study LIGHTHOUSE)

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 Lu-177) DOTATATE Therapy

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

Effect of hormonal therapy on F-fluciclovine PET/CT in the detection of prostate cancer recurrence, localization of metastatic disease, and correlation with prostate-specific antigen

Positivity Rate of F]Fluciclovine PET/CT in Patients with Suspected Prostate Cancer Recurrence at PSA Levels Below 1 ng/mL

Prostate Cancer Imaging with 18F-Fluciclovine

Collaborations(10)

Rachna Shroff

Hina Arif Tiwari

Brianna Denton

Diana Dawson

Shamar Young